WHAT IS CLAIMED IS:

1. A method for the treatment of diabetes mellitus comprising administering to a person afflicted with diabetes mellitus a therapeutic amount of an insulin sensitizer with a therapeutic amount of a drug selected from the group consisting of:

(a) an orally ingestible insulin;

(b) an injectible insulin;

(c) a sulfonylurea;

(d) a biguanide; and

(e) an alpha-glucosidase inhibitor.

2. A method as claimed in claim 1 comprising an insulin sensitizer and an orally ingestible insulin.

3. A method as claimed in claim 1 comprising an insulin sensitizer and and injectible insulin.

4. A method as claimed in claim 1 comprising an insulin sensitizer and a sulfonylurea.

5. A method as claimed in claim 1 comprising an insulin sensitizer and a biguanide.

6. A method as claimed in claim 1 comprising an insulin sensitizer and an alpha-glucosidase inhibitor.

7. A method as claimed in claim 1 including adding a pharmaceutical carrier to the therapeutically effective amount of drug.

8. A composition for the treatment of diabetes mellitus comprising:

(a) a therapeutic amount of an insulin sensitizer; and

(b) a therapeutic amount of a drug selected from

the group consisting of: an orally ingestible insulin; an injectible insulin; a sulfonylurea; a biguanide; and an alpha-glucosidase inhibitor.

Sub-B2

9.5 A composition for the treatment of diabetes mellitus in a mammal comprising:

(a) a therapeutically effective amount of an orally ingestible insulin which is formulated to withstand degradation by passage through the stomach and upper intestine of the mammal so that a therapeutically effective level of insulin reaches the bloodstream of the mammal; and,

(b) a therapeutically effective amount of one or more of a orally ingestible insulin sensitizer which withstands degradation by the stomach contents and upper intestinal tract of the mammal and reaches the bloodstream of the mammal and thereby sensitizes the cells of the mammal to enhance insulin uptake and/or utilization of glucose by the cells of the mammal thus reducing the orally ingested insulin required for a therapeutic dose.

10. A composition for the treatment of diabetes mellitus comprising:

(a) a therapeutically effective amount of an injected insulin; and,

(b) a therapeutically effective amount of one or more insulin sensitizers to sensitize the cells of the mammal so as to enhance insulin uptake and/or utilization of glucose by the cells of the mammal thus reducing the therapeutic dose required of injected insulin.

11. A composition for the treatment of diabetes mellitus in a mammal comprising:

(a) a therapeutically effective amount of a sulfonylurea; and,

(b) a therapeutically effective amount of one or more insulin sensitizers to sensitize the cells of the

mammal so as to enhance insulin uptake and/or utilization of glucose by the cells of the mammal thus reducing the therapeutic dose required of the sulfonylurea.

12. A composition for the treatment of diabetes mellitus in a mammal comprising:

(a) a therapeutically effective amount of a biguanide; and,

(b) a therapeutically effective amount of one or more insulin sensitizers to sensitize the cells of the mammal so as to enhance insulin uptake and/or utilization of glucose by the cells of the mammal thus reducing the therapeutic dose required of the biguanide.

13. A composition for the treatment of diabetes mellitus comprising:

(a) a therapeutically effective amount of an alpha-glucosidase inhibitor; and,

(b) a therapeutically effective amount of one or more insulin sensitizers to sensitize the cells of the mammal so as to enhance insulin uptake and/or utilization of glucose by the cells of the mammal thus reducing the therapeutic dose required of the alpha-glucosidase inhibitor.

14. A composition as claimed in claim 5 including a pharmaceutically acceptable carrier.

15. A composition as claimed in claim 10 including a pharmaceutically acceptable carrier.

16. A composition as claimed in claim 11 including a pharmaceutically acceptable carrier.

17. A composition as claimed in claim 12 including a pharmaceutically acceptable carrier.

18. A composition as claimed in claim 13 including a pharmaceutically acceptable carrier.

19. A composition as claimed in claim 9 wherein the insulin is synthetic insulin.

20. A composition as claimed in claim 10 wherein the insulin is synthetic insulin.

21. A composition as claimed in claim 9 wherein the orally ingestible insulin is present in the composition in the range of about 1 mcg to 100 mg and the insulin sensitizer is present in the composition in the range of about 10 mcg to 10 mg.

22. A composition as claimed in claim 10 wherein the injected insulin is present in the composition in the range of about 1 mcg to 100 mg and the insulin sensitizer is present in the composition in the range of about 10 mcg to 10 mg.

23. Any composition as claimed in claim 9 wherein the insulin sensitizer is present in the composition in the range of about 10 mcg to 10 mg.

24. A composition as claimed in claim 10 wherein the insulin sensitizer is present in the composition in the range of about 10 mcg to 10 mg.

25. A composition as claimed in claim 11 wherein the insulin sensitizer is present in the composition in the range of about 10 mcg to 10 mg.

26. A composition as claimed in claim 12 wherein the insulin sensitizer is present in the composition in the range of about 10 mcg to 10 mg.

27. A composition as claimed in claim 13 wherein the insulin sensitizer is present in the composition in the range of about 10 mcg to 10 mg.

28. A composition as claimed in claim 8 wherein the insulin sensitizer is selected from the group consisting of BRL-49653, Pioglitazone HCL, Troglitazone, MC 555, ALRT 268, LGD 1069, Chromic Picolinate and V-411.

29. A composition as claimed in claim 12 wherein the biguanide is glucophage.